{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:18:10Z","timestamp":1793744290636,"version":"4.6.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Targeting mitochondrial oxidative phosphorylation (OXPHOS) enhances the effects of standard chemotherapy and overcomes treatment resistance in preclinical models of acute myeloid leukemia (AML). So far, the few clinically available OXPHOS inhibitors have shown adverse effects or limited potency in clinical trials; therefore, the identification of safe and effective drugs that target mitochondrial metabolism in AML is critical. Here, we performed a high-throughput drug-repurposing screen designed to identify clinically applicable OXPHOS-specific inhibitors through nutrient sensing. We uncover itraconazole, a US Food and Drug Administration\u2013approved antifungal compound, as a potent OXPHOS inhibitor in AML cells. Mechanistically, through stable isotope-assisted metabolomics and functional studies, we reveal that cytochrome P450 family 51 subfamily A member 1 (CYP51A1), which is part of the cytochrome P450 family and the prime target of azole antifungals, is involved in mitochondrial respiration and electron transport chain (ETC) complex I activity in AML cells. Critically, we demonstrate that itraconazole and related azole antifungals interfere with tricarboxylic acid cycle activity and inhibit OXPHOS through the inhibition of ETC complex I activity. Overexpression of yeast nicotinamide adenine dinucleotide (NADH) dehydrogenase-1 (NDI1) restored mitochondrial NADH oxidation and complex I activity following itraconazole treatment. Using patient-derived cells and preclinical xenograft models, we demonstrate that itraconazole targets therapy-resistant leukemic stem cells (LSCs) when used in combination with cytarabine, highlighting the repurposing potential for itraconazole as a clinically safe and effective therapeutic option for AML LSC eradication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027853","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:07:00Z","timestamp":1771970820000},"page":"2431-2447","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-8930","authenticated-orcid":false,"given":"Ekaterini","family":"Himonas","sequence":"first","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"},{"name":"2Cancer Genetics, Therapeutics & Ultrastructural Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"de Beauchamp","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Zerbst","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2954-0501","authenticated-orcid":false,"given":"Eudoxie","family":"Desmares-Romain","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Sarnello","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Kalkman","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-0017","authenticated-orcid":false,"given":"Kevin M.","family":"Rattigan","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-3673","authenticated-orcid":false,"given":"Daniel","family":"James","sequence":"additional","affiliation":[{"name":"6Cancer Research UK Scotland Institute, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5932-9332","authenticated-orcid":false,"given":"Engy","family":"Shokry","sequence":"additional","affiliation":[{"name":"6Cancer Research UK Scotland Institute, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[{"name":"7Paul O\u2019Gorman Leukaemia Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Griessinger","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"8Service d'H\u00e9matologie, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-9129","authenticated-orcid":false,"given":"V\u00e9ronique","family":"De Mas","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"8Service d'H\u00e9matologie, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4404","authenticated-orcid":false,"given":"Francois","family":"Vergez","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"8Service d'H\u00e9matologie, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-4079","authenticated-orcid":false,"given":"David","family":"Sumpton","sequence":"additional","affiliation":[{"name":"6Cancer Research UK Scotland Institute, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[{"name":"9Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"9Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-0956","authenticated-orcid":false,"given":"Eyal","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"10Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Shanks","sequence":"additional","affiliation":[{"name":"6Cancer Research UK Scotland Institute, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-2032","authenticated-orcid":false,"given":"Jean-Emmanuel","family":"Sarry","sequence":"additional","affiliation":[{"name":"3Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"4LabEx Toucan, Toulouse, France"},{"name":"5\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1616-132X","authenticated-orcid":false,"given":"G. Vignir","family":"Helgason","sequence":"additional","affiliation":[{"name":"1Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026052111220345800_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2026052111220345800_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.stem.2021.02.013","article-title":"Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors","volume":"28","author":"Jones","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"7661","key":"2026052111220345800_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"4","key":"2026052111220345800_bib4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2026052111220345800_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026052111220345800_bib6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2026052111220345800_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1607","article-title":"Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML","volume":"28","author":"Saito","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2026052111220345800_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2026052111220345800_bib9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"2026052111220345800_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"Skrtic","year":"2011","journal-title":"Cancer Cell"},{"issue":"7","key":"2026052111220345800_bib11","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"2026052111220345800_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem J"},{"issue":"5","key":"2026052111220345800_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","article-title":"First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors","volume":"40","author":"Janku","year":"2022","journal-title":"Invest New Drugs"},{"issue":"11","key":"2026052111220345800_bib14","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/cam4.845","article-title":"A phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia","volume":"5","author":"Reed","year":"2016","journal-title":"Cancer Med"},{"issue":"1","key":"2026052111220345800_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2026052111220345800_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0885-4505(92)90056-5","article-title":"Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts","volume":"48","author":"Robinson","year":"1992","journal-title":"Biochem Med Metab Biol"},{"issue":"2","key":"2026052111220345800_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","article-title":"Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants","volume":"97","author":"Marroquin","year":"2007","journal-title":"Toxicol Sci"},{"issue":"3","key":"2026052111220345800_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.1606","article-title":"Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis","volume":"28","author":"Gohil","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"751","key":"2026052111220345800_bib19","doi-asserted-by":"crossref","first-page":"eadi5336","DOI":"10.1126\/scitranslmed.adi5336","article-title":"Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia","volume":"16","author":"Khalaf","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026052111220345800_bib20","doi-asserted-by":"crossref","first-page":"45465","DOI":"10.1038\/srep45465","article-title":"Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation","volume":"7","author":"Heinz","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"2026052111220345800_bib21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1078-0432.CCR-13-1283","article-title":"Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia","volume":"20","author":"Gandhi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6453","key":"2026052111220345800_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"3","key":"2026052111220345800_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell"},{"issue":"3","key":"2026052111220345800_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"issue":"10","key":"2026052111220345800_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/ncb3233","article-title":"Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis","volume":"17","author":"Cardaci","year":"2015","journal-title":"Nat Cell Biol"},{"issue":"10","key":"2026052111220345800_bib26","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr Biol"},{"issue":"7494","key":"2026052111220345800_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13110","article-title":"Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides","volume":"508","author":"Birsoy","year":"2014","journal-title":"Nature"},{"issue":"16","key":"2026052111220345800_bib28","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1073\/pnas.95.16.9167","article-title":"Molecular remedy of complex I defects: rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells","volume":"95","author":"Seo","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026052111220345800_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/abbi.1996.0193","article-title":"The ubiquitously expressed human CYP51 encodes lanosterol 14 alpha-demethylase, a cytochrome P450 whose expression is regulated by oxysterols","volume":"329","author":"Stromstedt","year":"1996","journal-title":"Arch Biochem Biophys"},{"issue":"30","key":"2026052111220345800_bib30","doi-asserted-by":"crossref","first-page":"18075","DOI":"10.1016\/S0021-9258(17)44716-8","article-title":"NB-598: a potent competitive inhibitor of squalene epoxidase","volume":"265","author":"Horie","year":"1990","journal-title":"J Biol Chem"},{"issue":"3","key":"2026052111220345800_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"757","key":"2026052111220345800_bib32","doi-asserted-by":"crossref","first-page":"eadk1731","DOI":"10.1126\/scitranslmed.adk1731","article-title":"Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models","volume":"16","author":"Larrue","year":"2024","journal-title":"Sci Transl Med"},{"issue":"2","key":"2026052111220345800_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.leu.2403222","article-title":"NOD\/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration","volume":"18","author":"Nicolini","year":"2004","journal-title":"Leukemia"},{"issue":"12","key":"2026052111220345800_bib34","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1515\/bchm2.1967.348.1.1686","article-title":"[On growth of cancer cells in media in which glucose is replaced by galactose]","volume":"348","author":"Warburg","year":"1967","journal-title":"Hoppe Seylers Z Physiol Chem"},{"issue":"2","key":"2026052111220345800_bib35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","article-title":"Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants","volume":"97","author":"Marroquin","year":"2007","journal-title":"Toxicol Sci"},{"key":"2026052111220345800_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biocel.2016.08.029","article-title":"Circumventing the Crabtree effect: a method to induce lactate consumption and increase oxidative phosphorylation in cell culture","volume":"79","author":"Mot","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"2026052111220345800_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-016-2780-z","article-title":"Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era","volume":"36","author":"Keighley","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"2026052111220345800_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01701730","article-title":"Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia","volume":"67","author":"Vreugdenhil","year":"1993","journal-title":"Ann Hematol"},{"issue":"5","key":"2026052111220345800_bib39","first-page":"2481","article-title":"Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"issue":"2","key":"2026052111220345800_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"issue":"7","key":"2026052111220345800_bib41","first-page":"3839","article-title":"Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"issue":"5","key":"2026052111220345800_bib42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","article-title":"Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer","volume":"8","author":"Rudin","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"17","key":"2026052111220345800_bib43","doi-asserted-by":"crossref","first-page":"28510","DOI":"10.18632\/oncotarget.15324","article-title":"Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K\/mTOR signaling pathways","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2026052111220345800_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.biopha.2011.11.004","article-title":"Itraconazole inhibits HMEC-1 angiogenesis","volume":"66","author":"Del Carratore","year":"2012","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2026052111220345800_bib45","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI115154","article-title":"Reversal of daunorubicin resistance in P388\/ADR cells by itraconazole","volume":"87","author":"Gupta","year":"1991","journal-title":"J Clin Invest"},{"issue":"1612","key":"2026052111220345800_bib46","doi-asserted-by":"crossref","first-page":"20120431","DOI":"10.1098\/rstb.2012.0431","article-title":"Human cytochromes P450 in health and disease","volume":"368","author":"Nebert","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"9","key":"2026052111220345800_bib47","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/(SICI)1097-0061(19990630)15:9<755::AID-YEA417>3.0.CO;2-8","article-title":"Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents","volume":"15","author":"Lamb","year":"1999","journal-title":"Yeast"},{"issue":"10","key":"2026052111220345800_bib48","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.0910872107","article-title":"Cholesterol trafficking is required for mTOR activation in endothelial cells","volume":"107","author":"Xu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2026052111220345800_bib49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2169\/internalmedicine.38.829","article-title":"Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery","volume":"38","author":"Imai","year":"1999","journal-title":"Intern Med"},{"issue":"4","key":"2026052111220345800_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/36.4.657","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia","volume":"36","author":"Prentice","year":"1995","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2026052111220345800_bib51","doi-asserted-by":"crossref","first-page":"eaau7314","DOI":"10.1126\/sciadv.aau7314","article-title":"Improving the metabolic fidelity of cancer models with a physiological cell culture medium","volume":"5","author":"Vande Voorde","year":"2019","journal-title":"Sci Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2431\/2521301\/blood_bld-2024-027853-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2431\/2521301\/blood_bld-2024-027853-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:22:16Z","timestamp":1779376936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/21\/2431\/566837\/A-metabolism-specific-drug-repurposing-screen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027853","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,21]]},"published":{"date-parts":[[2026,5,21]]}}}